These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 17166802)

  • 1. Disease-modifying trials in Alzheimer's disease: a European task force consensus.
    Vellas B; Andrieu S; Sampaio C; Wilcock G;
    Lancet Neurol; 2007 Jan; 6(1):56-62. PubMed ID: 17166802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endpoints for trials in Alzheimer's disease: a European task force consensus.
    Vellas B; Andrieu S; Sampaio C; Coley N; Wilcock G;
    Lancet Neurol; 2008 May; 7(5):436-50. PubMed ID: 18420157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.
    Hampel H; Lista S; Teipel SJ; Garaci F; Nisticò R; Blennow K; Zetterberg H; Bertram L; Duyckaerts C; Bakardjian H; Drzezga A; Colliot O; Epelbaum S; Broich K; Lehéricy S; Brice A; Khachaturian ZS; Aisen PS; Dubois B
    Biochem Pharmacol; 2014 Apr; 88(4):426-49. PubMed ID: 24275164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Recommendations concerning regulatory and legal aspects" contribution to the European task force on disease modifying trials in Alzheimer's disease.
    Rapp L
    J Nutr Health Aging; 2006; 10(2):139-41. PubMed ID: 16554950
    [No Abstract]   [Full Text] [Related]  

  • 5. Developing Treatment Guidelines for Alzheimer's Disease and Other Dementias.
    Rabins PV
    J Clin Psychiatry; 1998; 59 Suppl 11():17-9. PubMed ID: 9731546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining and labeling disease-modifying treatments for Alzheimer's disease.
    Cummings JL
    Alzheimers Dement; 2009 Sep; 5(5):406-18. PubMed ID: 19751920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.
    Siemers E; DeMattos RB; May PC; Dean RA
    Biomark Med; 2010 Feb; 4(1):81-9. PubMed ID: 20387304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
    Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
    Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying approaches to Alzheimer's disease: challenges and opportunities-Lessons from donepezil therapy.
    Sabbagh MN; Richardson S; Relkin N
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S109-18. PubMed ID: 18631986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease.
    Truffinet P; Bordet R; Ménard J
    Therapie; 2009; 64(3):139-8. PubMed ID: 19671425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention trials in Alzheimer's disease: an EU-US task force report.
    Vellas B; Aisen PS; Sampaio C; Carrillo M; Scheltens P; Scherrer B; Frisoni GB; Weiner M; Schneider L; Gauthier S; Gispen-de Wied CC; Hendrix S; Feldman H; Cedarbaum J; Petersen R; Siemers E; Andrieu S; Prvulovic D; Touchon J; Hampel H
    Prog Neurobiol; 2011 Dec; 95(4):594-600. PubMed ID: 21925234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.
    Gustavsson A; Cattelin F; Jönsson L
    Alzheimers Dement; 2011 Jul; 7(4):466-73. PubMed ID: 21784355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research design issues: antialuminum drug studies in Alzheimer's disease.
    Shore D; Wyatt RJ
    Clin Neuropharmacol; 1982 Dec; 5(4):337-43. PubMed ID: 7159877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The Alzheimer's disease: how to estimate the impact of the pathology and the treatment?].
    Delrieu J; Vellas B
    Therapie; 2010; 65(5):423-8. PubMed ID: 21144477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
    Gauthier S; Leuzy A; Racine E; Rosa-Neto P
    Prog Neurobiol; 2013 Nov; 110():102-13. PubMed ID: 23578568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Consensus statement of an interdisciplinary group of French experts on modalities of diagnosis and medical treatment of Alzheimer's disease at a treatable stage].
    Petit H; Bakchine S; Dubois B; Laurent B; Montagne B; Touchon J; Robert P; Vellas B; Vetel JM; Cogneau J; Marin La Meslée R; Sorbé G
    Rev Neurol (Paris); 1998 Jun; 154(5):432-8. PubMed ID: 9773080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
    Cummings J; Fox N; Vellas B; Aisen P; Shan G
    J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for the early stages of clinical development in Alzheimer's disease.
    Bordet R; Dartigues JF; Dubois B; Goehrs JM; Vernoux L; Semah F; Pasquier F; Bidaut-Mazel C;
    Therapie; 2010; 65(4):285-90, 277-283. PubMed ID: 20854749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease: clinical trials and drug development.
    Mangialasche F; Solomon A; Winblad B; Mecocci P; Kivipelto M
    Lancet Neurol; 2010 Jul; 9(7):702-16. PubMed ID: 20610346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.
    Paulino Ramirez Diaz S; Gil Gregório P; Manuel Ribera Casado J; Reynish E; Jean Ousset P; Vellas B; Salmon E
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):744-8. PubMed ID: 16035121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.